Open AccessRole of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer
Author(s) -
Mitsukuni Suenaga,
Shu Cao,
ZhiYing Wu,
Satoshi Matsusaka,
Satoshi Okazaki,
Martin D. Berger,
Yuji Miyamoto,
Marta Schirripa,
Afsaneh Barzi,
Norio Yamamoto,
Toshiharu Yamaguchi
Publication year - 2020
Publication title -
pharmacogenetics and genomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.579
H-Index - 140
eISSN - 1744-6880
pISSN - 1744-6872
DOI - 10.1097/fpc.0000000000000416
Subject(s) - medicine , hazard ratio , colorectal cancer , oncology , single nucleotide polymorphism , cohort , folfox , proportional hazards model , univariate analysis , stage (stratigraphy) , confidence interval , cancer , oxaliplatin , gastroenterology , multivariate analysis , genotype , biology , genetics , gene , paleontology
The enterocyte subtype of colorectal cancer (CRC) responds favorably to oxaliplatin-based adjuvant treatment for stage III CRC. We examined the clinical significance of single-nucleotide polymorphisms (SNPs) in enterocyte-related genes MS4A12 and CDX2 in response to adjuvant treatment for stage III CRC.